Please assess the completion status of the following clinical trial:

Trial Title: Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female subjects ≥ 18 to ≤ 75 years of age will be screened for eligibility.~* Eligible adult patients will have histologically proven sarcoidosis, diagnosed at least 6 months before screening, evidence of parenchymal disease on chest radiograph, an FVC between 50% and 85% of the predicted value, and a Medical Research Council dyspnea score (47) of at least grade 1.~* Patients must have been treated with at least 10 mg/day of prednisone or equivalent or one or more immunomodulating agents (hydroxychloroquine, methotrexate, azathioprine, leflunomide) for \>3 months before screening.~* Doses of these medications must be stable for at least 1 month before study entry.~* During the study, background medication regimen and doses are to remain stable.~Exclusion Criteria:~* active tobacco smoking or use of smokeless tobacco products containing nicotine,~* active cardiac or central nervous system disease,~* history of adverse reaction to nicotine or nicotine-containing products,~* patients with extensive irreversible pulmonary fibrosis (based upon lung biopsy or high resolution CT scan criterion) or inability to provide consent.~The subject will be excluded if they have a smoking history of greater than 20 pack years, or a diagnosis of other significant respiratory disorder other, than sarcoidosis that, in the opinion of the investigator, would complicate the evaluation of response to treatment; or, history of substance abuse (drugs or alcohol) within 3 years prior to screening or other circumstances (e.g., psychiatric disease) that could interfere with the subject's adherence to protocol requirements or increase their risk of drug (nicotine) dependence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Habitrol Nicotine patch - 7,14,21 mg patches Qd
- Control (Type: PLACEBO_COMPARATOR): Placebo patch

Based on this trial design, predict the completion outcome and termination type (if applicable).